News

January 21, 2021January 21, 2021

Zejula Now Available in UK as Maintenance Therapy for Advanced Ovarian Cancer

News

The National Institute of Health and Care Excellence (NICE) has recommended the use of Zejula (niraparib) as a maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal ... Read more

January 19, 2021January 19, 2021

UV1 Triple Combo Maintenance Therapy Will Be Tested in Phase 2 Trial

News

Ultimovacs will test its experimental cancer vaccine, UV1, as part of a triple-combination therapy for women with relapsed ovarian cancer who have no mutations in their BRCA DNA repair genes. ... Read more

January 14, 2021January 14, 2021

GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients

News

Combining the experimental vaccine galinpepimut-S (GPS) with the immune checkpoint inhibitor Keytruda (pembrolizumab) induces promising responses in people with metastatic ovarian cancer who failed one or two prior lines of treatment, ... Read more

January 12, 2021January 12, 2021

Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

News

Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in a ... Read more

January 7, 2021January 7, 2021

$34M Funding Helps Speed Up New Class of Cancer Diagnostics

News

InterVenn Biosciences has raised $34 million to commercialize a new diagnostic tool for ovarian cancer, based on the identification of circulating proteins containing sugar molecules (glycoproteins). The company expects to ... Read more

January 5, 2021January 5, 2021

Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy

News

Rubraca (rucaparib) is superior to chemotherapy at prolonging life without disease worsening in people with advanced ovarian cancer who received at least two prior lines of chemotherapy, according to top-line data ... Read more

December 22, 2020December 22, 2020

DPX-Survivac Responses Now Up to 16 Months in Advanced Ovarian Cancer Trial

News

IMV‘s immunotherapy DPX-Survivac plus low-dose chemotherapy continues to show sustained benefits in people with heavily treated advanced ovarian cancer, with some benefits lasting up to 16 months, updated findings from a ... Read more

December 17, 2020December 17, 2020

STRO-002 Continues to Show Promise in Phase 1 Trial for Advanced Ovarian Cancer

News

STRO-002, Sutro Biopharma’s experimental antibody-drug conjugate, continues to be safe and elicit promising responses in heavily pretreated patients with advanced ovarian cancer, according to the latest data from a Phase ... Read more

December 15, 2020December 15, 2020

$3.2M NIH Grant Supports Development of New Approach to Target ‘Invisible’ Residual Tumors

News

A $3.2-million grant from the National Institutes of Health has been awarded to the collaborative work between Northeastern University’s Spring Lab and Cellaria into a new method of eliminating the ... Read more

December 10, 2020December 10, 2020

Anixa Enters License Agreement With Cleveland Clinic for Ovarian Cancer Vaccine

News

Anixa Biosciences has entered in a license agreement with the Cleveland Clinic to obtain the exclusive, global rights for a new ovarian cancer vaccine technology. “Through this collaboration we are expanding ... Read more